Sign In
Buy COR
$263.64
-1.20 (-0.453%)
At Close: Jun 03, 2026
Cencora notifies individuals about data stolen earlier this year
09:55am, Friday, 24'th May 2024
U.S. drug distributor Cencora has notified affected individuals that their personal and highly sensitive medical information was stolen during a cyberattack and data breach earlier this year, the comp
Why Cencora (COR) is a Top Value Stock for the Long-Term
10:46am, Thursday, 23'rd May 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Walgreens Sells Another Stake In Distributor Cencora For $400 Million
08:35pm, Wednesday, 22'nd May 2024
Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $400 million, which will be used for “debt paydown and general corporate purposes.”
Cencora to buy $400 million in stock back from Walgreens
06:06pm, Wednesday, 22'nd May 2024
Cencora has agreed to buy about $400 million in stock back from Walgreens Boots Alliance, the second time the pharmacy chain has reduced its stake in the company this year as it looks to free up cash
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance and Raises Fiscal 2024 Guidance
05:44pm, Wednesday, 22'nd May 2024
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of ap
Walgreens Boots Alliance Sells Shares of Cencora for $400 Million of Proceeds
05:38pm, Wednesday, 22'nd May 2024
DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that it has sold shares of Cencora, Inc. (NYSE: COR) pursuant to a share repurchase by Cencora in the amo
Camino and Rio Tinto Both Acquire New Claims at Auction Nar the Los Chapitos Copper Project in Peru
06:00am, Friday, 17'th May 2024
VANCOUVER, BC / ACCESSWIRE / May 17, 2024 / Camino Corp. (TSXV:COR)(OTC PINK:CAMZF)(WKN:A116E1) ("Camino" or the "Company") is pleased to announce that it has increased its claims at its Los Chapitos
Cencora To Host Inaugural ThinkLive Cell and Gene Therapy Summit
09:35am, Tuesday, 14'th May 2024
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global healthcare company, will convene leaders from across the healthcare and biopharmaceutical industries for its inaugural ThinkLive Cell and Gene The
Cencora To Host Inaugural ThinkLive Cell and Gene Therapy Summit
08:30am, Wednesday, 08'th May 2024
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global healthcare company, will convene leaders from across the healthcare and biopharmaceutical industries for its inaugural ThinkLive Cell and Gene The
Cencora (COR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
11:01pm, Wednesday, 01'st May 2024
While the top- and bottom-line numbers for Cencora (COR) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to
Cencora, Inc. (COR) Q2 2024 Earnings Call Transcript
12:07pm, Wednesday, 01'st May 2024
Cencora, Inc. (NYSE:COR ) Q2 2024 Earnings Call Transcript May 1, 2024 8:30 AM ET Company Participants Bennett Murphy - SVP, Head of IR and Treasury Steve Collis - Chairman, President, and CEO Bob Mau
Cencora (COR) Q2 Earnings Top Estimates, 2024 View Raised
09:46am, Wednesday, 01'st May 2024
Cencora's (COR) second-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.
Cencora (COR) Q2 Earnings Top Estimates
08:41am, Wednesday, 01'st May 2024
Cencora (COR) came out with quarterly earnings of $3.80 per share, beating the Zacks Consensus Estimate of $3.65 per share. This compares to earnings of $3.50 per share a year ago.
Cencora beats profit estimates on strong demand for costly specialty drugs
07:43am, Wednesday, 01'st May 2024
Cencora beat Wall Street estimates for second-quarter profit on Wednesday, driven by robust demand for costly specialty medicines that treat complex diseases such as cancer and rheumatoid arthritis.
Cencora Reports Fiscal 2024 Second Quarter Results
06:30am, Wednesday, 01'st May 2024
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2024 second quarter ended March 31, 2024, revenue increased 7.8 percent year-over-year to $68.4 bil
